Biotech Startups

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform. The company focuses on preserving kidney function in patients with large, underserved populations affected by renal disease.

2 investors

Pykus Therapeutics is a clinical-stage medical technology company developing biodegradable polymers for vitreoretinal surgery. Its lead product, PYK-2101, is a biodegradable hydrogel intended to help patients recover from retina surgery faster and more comfortably.

2 investors

Q-Sera is a biotech company backed by Australian investors Uniseed and Brandon BioCatalyst, emerging from University of Queensland commercialisation efforts.

2 investors

Q Therapeutics develops allogeneic, human glial progenitor cell therapies for currently incurable diseases of the central nervous system. Its lead candidate, Q-Cells, is an off-the-shelf cell therapy that replaces myelin and supports neuron repair, with FDA allowance to begin a Phase 1/2a trial in Transverse Myelitis patients.

2 investors

QbDVision provides a software platform designed to address digital transformation challenges in pharmaceutical and biotech manufacturing, helping companies manage compliance, quality, and process development.

2 investors

Qihan Biotech uses multiplexable genome editing and immune shielding technologies in human stem cells and animal germline cells to develop immune-privileged cell and organ therapies. It works on applications spanning organs such as kidney, heart, lung, and liver, as well as cell types including islet cells, cardiomyocytes, neurons, and immune cells.

2 investors

Qnity builds a quantum-electrochemical chip using nanogold-silicon electrodes and quantum sensing to perform ultra-sensitive, real-time molecular screening and binding affinity analysis across molecule sizes, from small organics to biologics. The platform targets pharmaceutical and drug discovery use cases, including therapeutic development, drug prediction validation, and precision diagnostics.

2 investors

Qoniq provides data analysis and knowledge synthesis tools for Medical and Scientific Affairs professionals, helping them work with complex scientific datasets while augmenting rather than replacing human expertise.

2 investors

Develops lateral flow assay (LFA) diagnostic test kits for urine-based and blood-based testing, offering a range of products across various test panels. The kits include the test kit, manual, and desiccant.

2 investors

Qtas develops a quantum-sensor-based microscopy platform, described as the world's smallest MRI, that detects, sorts, and recovers intact individual rare cells (such as circulating tumor cells and rare immune cells) directly from unprocessed biological samples like whole blood or spinal fluid. The platform serves pharma, biotech, and liquid biopsy partners as an upstream tool feeding downstream molecular, genomic, proteomic, and single-cell analysis.

2 investors

Qu Biologics develops treatments aimed at cancer, chronic inflammatory diseases, and metabolic diseases by restoring normal immune function. It operates in the biotech and immunotherapy space.

2 investors

Quadriga BioSciences is an oncology startup developing targeted small molecule chemotherapeutics for cancer treatment, with a focus on central nervous system malignancies and immune-mediated disorders. The company works in partnership with leading academic oncology researchers and clinicians.

2 investors

QuantumCyte builds an AI-native precision tissue extraction platform that converts annotated regions of interest on FFPE tissue slides into molecular-ready samples for DNA, RNA, and protein analysis. It serves pathology and molecular diagnostics labs, using inkjet-printed polymer masking and on-slide lysis to isolate tumor cells and improve the purity of downstream sequencing results.

2 investors

QuantX Bio applies a proprietary computational platform to accelerate the discovery and optimization of drug candidates. The company operates in biotech, using computation to support drug discovery.

2 investors

QuberTech is a UK-based biotechnology company developing biotech tools to produce natural rubber from alternative crops grown in controlled environments, aiming to deliver traceable and sustainable materials. It targets the global natural rubber industry, addressing supply deficits, deforestation, and regulatory pressures such as the EU Deforestation Regulation.

2 investors

QUE Oncology develops Q-122, a non-hormonal therapeutic candidate in clinical development for treating vasomotor symptoms in postmenopausal women and cancer patients on hormone therapy. The company was formed as a joint venture between Emory University and University of Queensland's commercialization entity.

2 investors

Quince Therapeutics is a biotechnology company developing the AIDE technology platform, a drug/device combination that encapsulates medications into a patient's own red blood cells to improve drug delivery for rare diseases. The company's lead candidate, eDSP, completed a Phase 3 trial for ataxia-telangiectasia in January 2026 but failed to meet its primary efficacy endpoint; the company is now pursuing strategic alternatives including a potential reverse merger and has suspended further development of its product pipeline.

2 investors

Quorum Earth develops biopesticides aimed at controlling invasive insects, with an initial focus on protecting bees. The company positions its products in the agricultural pest control and biocontrol category.

2 investors

Qurcan develops veterinary pharmaceutical technology, with leadership holding advanced degrees in veterinary medicine, pharmaceutical sciences, and business development.

2 investors

QurieGen develops QuRIE-seq, a single-cell multi-omics platform that captures time-resolved single-cell data and trains lab-in-the-loop AI Virtual Cell models to predict cellular behavior and drug response. Spun out of the Huck Lab at Radboud University, the company serves pharmaceutical drug discovery and R&D.

2 investors

Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.

2 investors

RadioNano Therapeutics develops boron neutron capture therapy (BNCT), an advanced radiotherapy targeting cancer cells. The company is commercializing RN-501, a nanoparticle-enhanced therapeutic drug aimed at improving treatment safety and efficacy for cancer patients.

2 investors

Radionetics develops small molecule radiopharmaceuticals targeting GPCRs for cancer therapy and diagnosis, using a precision medicine approach that combines radioisotopes with potent, selective ligands. The company is headquartered in San Diego, California, and focuses on theranostic applications in oncology.

2 investors

2 investors